RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, will ring The Opening Bell® of the New York Stock Exchange (NYSE) on Wednesday, September 23, 2015 to celebrate the recently closed acquisition of the surgical robotic division of SOFAR S.p.A. TransEnterix has been a NYSE MKT listed company since April 2014.
"TransEnterix is proud to ring the opening bell on behalf of our entire team and investors in celebration of our recently completed acquisition of SOFAR’s surgical robotic division. This transaction supports our vision of transforming robotic surgery for patients, surgeons and hospitals," said Todd M. Pope, President and CEO of TransEnterix. "These are exciting times at TransEnterix, and we look forward to continuing on our journey with the NYSE."
Mr. Pope will be joined by Andrea Biffi, CEO of SOFAR and a member of the TransEnterix Board of Directors, along with several other members of the TransEnterix and SOFAR management teams as he rings the opening bell at 9:30am EST on September 23, 2015. A live feed of the NYSE Opening Bell (9:26 a.m. ET) can be found at www.livestream.com/NYSE. Photos and video of the NYSE Bell Ringing Ceremony will also be available, courtesy of the NYSE, on Facebook (NYSE), Twitter (@NYSE and @NYSECam), and YouTube (nysetv1).
TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the development and commercialization of the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform, and the commercialization of ALF-X®, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye tracking camera control. The SurgiBot System is not yet available for sale in any market. The ALF-X has been granted a CE Mark but is not available for sale in the US. For more information, visit the TransEnterix website at www.transenterix.com.
This press release includes statements relating to TransEnterix’s recent acquisition of SOFAR S.p.A’s. surgical robotics division. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, whether our acquisition of the ALF-X surgical robotics system will be successful, whether the combination of the SurgiBot and ALF-X supports our vision of transforming robotic surgery for patients, surgeons and hospitals; whether SurgiBot System's 510(k) application(s) submitted on June 1, 2015 will be cleared by the U.S. FDA, whether we will be able to efficiently and successfully integrate the acquisition into our operations, the pace of adoption of our products by surgeons, the success and market opportunity of our products, the effect on our business of existing and new regulatory requirements and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q filed on August 6, 2015 and other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.